Crossmark

Instability of high polygenic risk classification and mitigation by integrative scoring

Crossref DOI link: https://doi.org/10.1038/s41467-025-56945-0

Published Online: 2025-02-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Misra, Anika https://orcid.org/0009-0002-6217-0948
Truong, Buu https://orcid.org/0000-0003-0043-0812
Urbut, Sarah M. https://orcid.org/0000-0002-1135-9647
Sui, Yang

Fahed, Akl C.

Smoller, Jordan W.

Patel, Aniruddh P. https://orcid.org/0000-0001-7871-9638
Natarajan, Pradeep https://orcid.org/0000-0001-8402-7435
Funding

Funding for this research was provided by:

U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (R01HL1427)

U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (R01HL148565)

U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (R01HL148050)

U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (K08HL161448)

U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (R01HL164629)

U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (K08HL168238)

U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (R01HL169015)

U.S. Department of Health & Human Services | NIH | National Human Genome Research Institute (U01HG011719)

U.S. Department of Health & Human Services | NIH | National Human Genome Research Institute (T32HG010464)

U.S. Department of Health & Human Services | NIH | National Human Genome Research Institute (R01HG012354)

U.S. Department of Health & Human Services | NIH | National Human Genome Research Institute (U01HG011719)
License Information

Text and Data Mining valid from 2025-02-12

Version of Record valid from 2025-02-12
More Information

Article History

Received: 15 August 2024

Accepted: 6 February 2025

First Online: 12 February 2025

Competing interests

: A.C.F. reports being a co-founder of Goodpath, serving as scientific advisor to MyOme and HeartFlow, and receiving a research grant from Foresite Labs. J.W.S. is a member of the Scientific Advisory Board of Sensorium Therapeutics (with options), has received grant support from Biogen, Inc., and is PI of a collaborative study of the genetics of depression and bipolar disorder sponsored by 23andMe for which 23andMe provides analysis time as in-kind support but no payments. P.N. reports research grants from Allelica, Amgen, Apple, Boston Scientific, Genentech / Roche, and Novartis, personal fees from Allelica, Apple, AstraZeneca, Blackstone Life Sciences, Creative Education Concepts, CRISPR Therapeutics, Eli Lilly & Co, Esperion Therapeutics, Foresite Labs, Genentech / Roche, GV, HeartFlow, Magnet Biomedicine, Merck, Novartis, TenSixteen Bio, and Tourmaline Bio, equity in Bolt, Candela, Mercury, MyOme, Parameter Health, Preciseli, and TenSixteen Bio, and spousal employment at Vertex Pharmaceuticals, all unrelated to the present work. The remaining authors declare no competing interests.

Document is current

Any future updates will be listed below